Plunkett Research Online: Portola Pharmaceuticals Inc

PORTOLA PHARMACEUTICALS INC (PTLA:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Portola Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The firm’s first marketed medicine is the FDA-approved Bevyxxa (betrixaban), an oral, once-da.....



Portola Pharmaceuticals Inc
Ticker: PTLA
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 650-246-7300
Fax:
Address: 270 East Grand Avenue
South San Francisco, CA 94080 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Discovery & Development
ContactsDescription
William LisCEO/Director
Mardi DierCFO/Chief Accounting Officer/Executive VP/Co- President
See More
Portola Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The firm’s first marketed medicine is the FDA-approved Bevyxxa (betrixaban), an oral, once-da.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201720162015201420132012
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Bevyxxa
andexanet alfa
cerdulatinib
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: